Luis Valda RodriguezJean-Pierre DedetVirginia ParedtesCristo A Carrasco MendozaFernando Cárdenas2026-03-222026-03-22199510.1590/s0074-02761995000400020https://doi.org/10.1590/s0074-02761995000400020https://andeanlibrary.org/handle/123456789/48232Citaciones: 25A randomized trial of amphotericin B (AB) alone and in combination with oral itraconazole (IZ) is carried out in two groups of 10 mucocutaneous leishmaniasis patients from Bolivia and Peru. AB+IZ combination is no better than AB monotherapy, as far as efficacy and tolerability are concerned. No antagonism was detected.enItraconazoleTolerabilityAmphotericin BLeishmaniasisMedicineMucocutaneous zoneRandomized controlled trialAntagonismDermatologyInternal medicinearticle